Teva UK Limited and Closed Loop Medicine have joined forces in a strategic partnership to advance the development of personalised medicines. This collaboration aims to tackle the challenges associated with traditional dosing methods by leveraging Closed Loop Medicine's proprietary software alongside Teva's pharmaceutical products. By integrating digital care with drug therapy, the partnership seeks to enhance medication efficacy and improve patient outcomes, particularly in cases of chronic disorders where personalised dosing is crucial.
Closed Loop Medicine's software as a medical device (SaMD) technology platform holds the promise of revolutionising the way medications are prescribed and administered. By customising dosage levels based on individual patient needs, the partnership aims to minimise adverse events and increase medication adherence. Recent clinical trials, including one focused on hypertension treatment, have demonstrated the potential of this approach in optimising drug therapy while reducing side effects and ensuring better control over medical conditions.
The collaboration represents a significant step forward in the pursuit of personalised medicine within the healthcare system. By combining Teva's expertise in pharmaceuticals with Closed Loop Medicine's innovative digital solutions, the partnership aims to address the limitations of the "one size fits all" approach to medication. This initiative not only holds promise for improving patient experiences and outcomes but also has the potential to alleviate healthcare costs associated with non-optimized medication usage, marking a transformative shift in healthcare delivery towards a more tailored and effective model.
Click here to read the original news story.